AIMS: This study examined the functional role of B-type natriuretic peptide (BNP) in epoxyeicosatrienoic acid (EET)-mediated cardioprotection in mice with targeted disruption of the sEH or Ephx2 gene (sEH null). METHODS AND RESULTS: Isolated mouse hearts were perfused in the Langendorff mode and subjected to global no-flow ischaemia followed by reperfusion. Hearts were analysed for recovery of left ventricular developed pressure (LVDP), mRNA levels, and protein expression. Naïve hearts from sEH null mice had similar expression of preproBNP (Nppb) mRNA compared with wild-type (WT) hearts. However, significant increases in Nppb mRNA and BNP protein expression occurred during post-ischaemic reperfusion and correlated with improved post-ischaemic recovery of LVDP. Perfusion with the putative EET receptor antagonist 14,15-epoxyeicosa-5(Z)-enoic acid prior to ischaemia reduced the preproBNP mRNA in sEH null hearts. Inhibitor studies demonstrated that perfusion with the natriuretic peptide receptor type-A (NPR-A) antagonist, A71915, limited the improved recovery in recombinant full-length mouse BNP (rBNP)- and 11,12-EET-perfused hearts as well as in sEH null mice. Increased expression of phosphorylated protein kinase C epsilon and Akt were found in WT hearts perfused with either 11,12-EET or rBNP, while mitochondrial glycogen synthase kinase-3beta was significantly lower in the same samples. Furthermore, treatment with the phosphoinositide 3-kinase (PI3K) inhibitor wortmannin abolished improved LVDP recovery in 11,12-EET-treated hearts but not did significantly inhibit recovery of rBNP-treated hearts. CONCLUSION: Taken together, these data indicate that EET-mediated cardioprotection involves BNP and PI3K signalling events.
AIMS: This study examined the functional role of B-type natriuretic peptide (BNP) in epoxyeicosatrienoic acid (EET)-mediated cardioprotection in mice with targeted disruption of the sEH or Ephx2 gene (sEH null). METHODS AND RESULTS: Isolated mouse hearts were perfused in the Langendorff mode and subjected to global no-flow ischaemia followed by reperfusion. Hearts were analysed for recovery of left ventricular developed pressure (LVDP), mRNA levels, and protein expression. Naïve hearts from sEH null mice had similar expression of preproBNP (Nppb) mRNA compared with wild-type (WT) hearts. However, significant increases in Nppb mRNA and BNP protein expression occurred during post-ischaemic reperfusion and correlated with improved post-ischaemic recovery of LVDP. Perfusion with the putative EET receptor antagonist 14,15-epoxyeicosa-5(Z)-enoic acid prior to ischaemia reduced the preproBNP mRNA in sEH null hearts. Inhibitor studies demonstrated that perfusion with the natriuretic peptide receptor type-A (NPR-A) antagonist, A71915, limited the improved recovery in recombinant full-length mouseBNP (rBNP)- and 11,12-EET-perfused hearts as well as in sEH null mice. Increased expression of phosphorylated protein kinase C epsilon and Akt were found in WT hearts perfused with either 11,12-EET or rBNP, while mitochondrial glycogen synthase kinase-3beta was significantly lower in the same samples. Furthermore, treatment with the phosphoinositide 3-kinase (PI3K) inhibitor wortmannin abolished improved LVDP recovery in 11,12-EET-treated hearts but not did significantly inhibit recovery of rBNP-treated hearts. CONCLUSION: Taken together, these data indicate that EET-mediated cardioprotection involves BNP and PI3K signalling events.
Authors: Xiang Fang; Neal L Weintraub; Ryan B McCaw; Shanming Hu; Shawn D Harmon; James B Rice; Bruce D Hammock; Arthur A Spector Journal: Am J Physiol Heart Circ Physiol Date: 2004-07-29 Impact factor: 4.733
Authors: Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis Journal: Cancer Cell Date: 2007-01 Impact factor: 31.743
Authors: John M Seubert; Christopher J Sinal; Joan Graves; Laura M DeGraff; J Alyce Bradbury; Craig R Lee; Kerry Goralski; Michelle A Carey; Ayala Luria; John W Newman; Bruce D Hammock; John R Falck; Holly Roberts; Howard A Rockman; Elizabeth Murphy; Darryl C Zeldin Journal: Circ Res Date: 2006-07-20 Impact factor: 17.367
Authors: T Pain; X M Yang; S D Critz; Y Yue; A Nakano; G S Liu; G Heusch; M V Cohen; J M Downey Journal: Circ Res Date: 2000-09-15 Impact factor: 17.367
Authors: S N Batchu; S B Lee; R S Qadhi; K R Chaudhary; H El-Sikhry; R Kodela; J R Falck; J M Seubert Journal: Br J Pharmacol Date: 2011-02 Impact factor: 8.739
Authors: Komal Sodhi; Nitin Puri; Kazuyoshi Inoue; John R Falck; Michal L Schwartzman; Nader G Abraham Journal: Prostaglandins Other Lipid Mediat Date: 2011-12-24 Impact factor: 3.072
Authors: Matthew L Edin; Zhongjing Wang; J Alyce Bradbury; Joan P Graves; Fred B Lih; Laura M DeGraff; Julie F Foley; Robert Torphy; Oline K Ronnekleiv; Kenneth B Tomer; Craig R Lee; Darryl C Zeldin Journal: FASEB J Date: 2011-06-22 Impact factor: 5.191
Authors: Garrett J Gross; John E Baker; Anna Hsu; Hsiang-en Wu; John R Falck; Kasem Nithipatikom Journal: Am J Physiol Heart Circ Physiol Date: 2010-04-16 Impact factor: 4.733
Authors: Ketul R Chaudhary; Mohamed Abukhashim; Sung Hee Hwang; Bruce D Hammock; John M Seubert Journal: J Cardiovasc Pharmacol Date: 2010-01 Impact factor: 3.105
Authors: Ketul R Chaudhary; Beshay N M Zordoky; Matthew L Edin; Nasser Alsaleh; Ayman O S El-Kadi; Darryl C Zeldin; John M Seubert Journal: Prostaglandins Other Lipid Mediat Date: 2012-08-16 Impact factor: 3.072
Authors: Kathleen Guglielmino; Kaleena Jackson; Todd R Harris; Vincent Vu; Hua Dong; Gavin Dutrow; James E Evans; James Graham; Bethany P Cummings; Peter J Havel; Nipavan Chiamvimonvat; Sanda Despa; Bruce D Hammock; Florin Despa Journal: Am J Physiol Heart Circ Physiol Date: 2012-08-03 Impact factor: 4.733